SS
OTLK icon

SBI Securities’s Outlook Therapeutics OTLK Stock Holding History

SBI Securities’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46 Buy
222
+12
+6% +$5 ﹤0.01% 3594
2025
Q4 		$332 Hold
210
– – ﹤0.01% 3028
2025
Q3 		$223 Hold
210
– – ﹤0.01% 3278
2025
Q2 		$336 Hold
210
– – ﹤0.01% 3126
2025
Q1 		$256 Hold
210
– – ﹤0.01% 3131
2024
Q4 		$397 Buy
+210
New +$864 ﹤0.01% 2980

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

SBI Securities's OTLK Position: Q1 2026 in Review

SBI Securities increased its Outlook Therapeutics (OTLK) stake by 5.7% in Q1 2026, buying an estimated $5 and bringing the position to 222 shares worth $46. The position accounts for ﹤0.01% of the portfolio, ranked #3594.

SBI Securities first reported a position in OTLK in Q4 2024 and has held it in 6 quarters since. The position peaked at $397 in Q4 2024. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • SBI Securities held 222 shares of Outlook Therapeutics worth $46 as of Q1 2026.
  • SBI Securities bought 12 Outlook Therapeutics shares in Q1 2026, an estimated $5.
  • Outlook Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3594 holding.
  • SBI Securities first reported a position in Outlook Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Outlook Therapeutics position peaked at $397 in Q4 2024.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.